High Frequency (10 kHz) or Burst Spinal Cord Stimulation in Failed Back Surgery Syndrome Patients With Predominant Back Pain: Preliminary Data From a Prospective Observational Study.

Journal: Neuromodulation : Journal Of The International Neuromodulation Society
Published:
Abstract

Background: Conventional spinal cord stimulation (SCS) exhibits pain relief and improved quality of life in refractory failed back surgery syndrome. However, patients suffering from predominant back pain failed to achieve a favorable neuromodulation outcome. Currently, two new stimulation concepts, the burst and the HF10 stimulation paradigms successfully suppress intractable back pain levels in this difficult-to-treat subgroup. To date, literature data comparing both stimulation patterns is lacking.

Methods: A prospective, observational study was conducted including 16 refractory Failed-back surgery syndrome (FBSS) patients with previous spine surgery and predominant back pain (70% of overall pain) with or without leg pain eligible for burst or high-frequency SCS. At baseline and at a three-month follow-up the pain intensity (back pain (VASB )/leg pain (VASL ), sleep quality (Pittsburgh Sleep Quality Index [PSQI]), changes in severity of depressive symptoms (Beck Depression Inventory [BDI]) and any adverse event related to the implantation and the stimulation were recorded.

Results: Overall baseline VASB was significantly suppressed in 14 FBSS patients (eight burst/six patients with 10 HF10) from baseline 7.9 ± 0.7 to 2.3 ± 1 (p < 0.001), while the overall VASL declined significantly from 3.1 ± 1.5 to 1.9 ± 0.83 (p < 0.01). The burst patients experienced significant VASL reduction (burst 1.8 ± 0.7 (p < 0.009) compared to HF10 patients 2.2 ± 1). Two patients failed 10 HF10-trial. The BDI [23.3 ± 2.1 to 13.5 ± 4.5 (p < 0.001)] and the PSQI [7.6 ± 3.7 to 4.2 ± 1.4 (p < 0.003)] dropped down significantly for both modalities. No implantation/stimulation-related complications were observed.

Conclusions: Burst and HF10 SCS performed efficiently and safely in intractable FBSS patients with predominant back pain and deserve more refined, specific investigations to determine their efficacy.